Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 2, 2014, Pages 372-379

  Takeda, Atsuya ^a,b   Sanuki, Naoko ^a,b   Eriguchi, Takahisa ^a,b   Kobayashi, Takashi ^d   Iwabutchi, Shogo ^b   Matsunaga, Kotaro ^b   Mizuno, Tomikazu ^c   Yashiro, Kae ^c   Nisimura, Shuichi ^a,b   Kunieda, Etsuo ^e  

^a Radiation Oncology Center   (Japan)

^b Div of Gastroenterology/Hepatology   (Japan)

^c OFUNA CHUO HOSPITAL   (Japan)

^d TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

^e TOKAI UNIVERSITY   (Japan)

Author keywords

Curative treatment; Hepatocellular carcinoma; SABR; SBRT; Stereotactic body radiotherapy

Indexed keywords

ANTIVIRUS AGENT; DIURETIC AGENT; EPIRUBICIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; ASCITES; CANCER CONTROL; CANCER PATIENT; CANCER SURGERY; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; LIVER TOXICITY; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; RADIOFREQUENCY ABLATION; STEREOTACTIC ABLATIVE BODY RADIOTHERAPY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; TUMOR VOLUME; CURATIVE TREATMENT; LIVER TUMOR; MIDDLE AGED; MORTALITY; RADIOGRAPHY; RADIOSURGERY; RETROSPECTIVE STUDY; SABR; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

CURATIVE TREATMENT; HEPATOCELLULAR CARCINOMA; SABR; SBRT; STEREOTACTIC BODY RADIOTHERAPY;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIOSURGERY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84884315553     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12350     Document Type: Article

References (36)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943.
3. Arii S, Sata M, Sakamoto M etal. Management of hepatocellular carcinoma: report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol. Res. 2010; 40: 667-685.
4. Ikai I, Kudo M, Arii S etal. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol. Res. 2010; 40: 1043-1059.
5. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52 (Suppl. 3): iii1-8.
6. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less. Gut 2005; 54: 1151-1156.
7. Rhim H, Lim HK. Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: the value of artificial ascites. Abdom. Imaging 2009; 34: 371-380.
8. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother. Oncol. 2010; 94: 1-11.
9. Louis C, Dewas S, Mirabel X etal. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol. Cancer Res. Treat. 2010; 9: 479-487.
10. Andolino DL, Johnson CS, Maluccio M etal. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: e447-453.
11. Kang JK, Kim MS, Cho CK etal. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012; 118: 5424-5431.
12. Tse RV, Hawkins M, Lockwood G etal. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Clin. Oncol. 2008; 26: 657-664.
13. Lok AS, Ghany MG, Goodman ZD etal. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42: 282-292.
14. Murakami T, Imai Y, Okada M etal. Ultrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: toward improved treatment decisions. Oncology 2011; 81 (Suppl. 1): 86-99.
15. Edge SB, Byrd DR, Compton CC etal. AJCC Cancer Staging Handbook, 7th edn. New York: Springer, 2010.
16. Takeda A, Kunieda E, Shigematsu N etal. Small lung tumors: long-scan-time CT for planning of hypofractionated stereotactic radiation therapy-initial findings. Radiology 2005; 237: 295-300.
17. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010; 30: 52-60.
18. Ishizawa T, Hasegawa K, Aoki T etal. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916.
19. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-1440.
20. Torzilli G, Makuuchi M, Inoue K etal. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch. Surg. 1999; 134: 984-992.
21. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 2010; 30: 61-74.
22. Shiina S, Teratani T, Obi S etal. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130.
23. Lencioni RA, Allgaier HP, Cioni D etal. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240.
24. Brunello F, Veltri A, Carucci P etal. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand. J. Gastroenterol. 2008; 43: 727-735.
25. Sala M, Llovet JM, Vilana R etal. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-1360.
26. Miyayama S, Matsui O, Yamashiro M etal. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J. Vasc. Interv. Radiol. 2007; 18: 365-376.
27. Takayasu K, Arii S, Kudo M etal. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J. Hepatol. 2012; 56: 886-892.
28. Salem R, Lewandowski RJ, Kulik L etal. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507 e2.
29. Sangro B, Carpanese L, Cianni R etal. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-878.
30. Takeda A, Takahashi M, Kunieda E etal. Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: preliminary results for efficacy and toxicity. Hepatol. Res. 2008; 38: 60-69.
31. Shi M, Guo RP, Lin XJ etal. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann. Surg. 2007; 245: 36-43.
32. Imamura H, Matsuyama Y, Tanaka E etal. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 2003; 38: 200-207.
33. Eriguchi T, Takeda A, Sanuki N etal. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int. J. Radiat. Oncol. Biol. Phys. 2013; 85: 1006-1011.
34. Kudo M, Arii S, Ikai I etal. Report of the 18th follow-up survey of primary liver cancer in Japan. Osaka-Sayama: Liver Cancer Study Group of Japan, 2009.
35. Bae SH, Kim MS, Cho CK etal. Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 2012; 84: e469-474.
36. Pan CC, Kavanagh BD, Dawson LA etal. Radiation-associated liver injury. Int. J. Radiat. Oncol. Biol. Phys. 2010; 76: S94-100.